Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials

BACKGROUND: Non-small cell lung cancer (NSCLC) with HER2 mutation has entered into the era of targeted therapy. However, both anti-HER2 antibody–drug conjugates (ADCs) and tyrosine kinase inhibitors (TKIs) showed moderate objective response rate (ORR) and median progression-free survival (PFS). The...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Shiqi, Yang, Shuo, Liu, Xinyu, Li, Xingya, Wang, Qiming, Zhang, Yiping, Chen, Jianhua, Wang, Yan, Gao, Guanghui, Wu, Fengying, Jiang, Tao, Zhang, Jiao, Yang, Ying, Lin, Xiang, Zhu, Xiaoyu, Zhou, Caicun, Ren, Shengxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251549/
https://www.ncbi.nlm.nih.gov/pubmed/37296463
http://dx.doi.org/10.1186/s40164-023-00417-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251549/
https://www.ncbi.nlm.nih.gov/pubmed/37296463
http://dx.doi.org/10.1186/s40164-023-00417-y

Ejemplares similares